Update Series (2015) Lesson 13: Principles of Immunotherapy of Genitourinary Cancer
For the most timely topics and latest surgical techniques in urology, you won’t want to miss the 2015 AUA Update Series—the AUA’s most popular self-study CME product.
All new topics for 2015!
- New Digital Publication (dPub) format with enhanced links and navigation
- New print edition with bookshelf-quality binding
- Concise, practical lessons on timely topics
- State-of-the-art surgical techniques
- Authors are among the best in their specialties
Earn up to 40 AMA PRA Category 1 Credits™
Now in its 34th installment, this invaluable resource continues the tradition of providing up-to-date information that helps you fulfill Part 2 of the Maintenance of Certification requirements recognized by the American Board of Urology. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology.
Benefit from leading urologists’ recommendations in 40 new lessons, which are delivered to you five lessons a month for eight months. For about $10 per lesson, you can take advantage of convenient, easy-to-access lessons that fit your individual learning style.
Subscribers receive CME credit instantly! Simply complete the content-related, online posttests to receive instant CME credit.
The AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed in consultation with and edited by internationally recognized experts in urology, making AUA Update Series the most professional and sought-after self-study program available.
Hot Topics for 2015:
- Management of Emergency Bleeding, Recalcitrant Clots and Hemorrhagic Cystitis
- Where does SWL Fit? Technology, Patient Selection and Procedure
- Gene Expression Testing for Prostate Cancer: Indications and Impact
- Botox in the Lower Urinary Tract in Adults and Children – Technique
- Ethics and Regulatory Compliance in Urology Clinical Trials
- Dealing with a Difficult Patient
- Contemporary Management of Advanced Prostate Cancer
- Cryptorchidism – 2014 AUA Guideline
- Genetics of Renal Cancer
- Urotauma – 2014 AUA Guideline
- Medical Management of Stones – 2014 AUA Guideline
- Treatment of Pelvic Organ Prolapse in the Frail Elderly, Patient
The American Urological Association designates this enduring material for a maximum of 40 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
At the conclusion of this continuing medical education activity, theparticipant will be knowledgeable in fundamental principles of tumor immunology;cognizant of current FDA approved cancer immunotherapies for genitourinarymalignancies including their proposed mechanism of action, specific indications, efficacyand side effects; and able to understand biological significance of immune co-signalingin T cell function as well as the key principles in cancer immuno-editing.
Robert S. Svatek, MD, MSCI
Disclosures: Merck: Consultant
Tyler J. Curiel, MD, MPH
Disclosures: Eisai: Consultant
The University of Texas Health Science Center San Antonio
San Antonio, Texas
NOTE: CME is no longer available for this activity.
This self-study continuing medical education activity is designed to provide urologists, Board candidates and/or residents affordable and convenient access to the most recent developments and techniques in urology.
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation: The American Urological Association designates this enduring material for a maximum of 40.0 AMA PRA Category 1 CreditsTM.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME enduring material activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is feltto be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Reproduction Permission: Reproduction of written materials developed for this AUA activity is prohibited without the written permission fromindividual authors and the American Urological Association.
Peer Review: Peer review is the principle mechanism by which the quality of the AUA Update Series content is judged by the AUA Update Series Advisory Board.
Released date: Month, 2015
Expiration date: Month, 2018
AUAER Privacy and Confidentiality Policy
Email the AUA Office of Education with any questions at email@example.com
©2015 American Urological Association,